超薄支柱药物洗脱支架的叙述性综述：越薄越好？
A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?
作者信息
Grundeken Maik J, Beijk Marcel Am
机构信息
Department of Cardiology, Amsterdam University Medical Centre - location AMC, Amsterdam, The Netherlands.
出版信息
Heart Int. 2021 Dec 21;15(2):84-93. doi: 10.17925/HI.2021.15.2.84. eCollection 2021.
Abstract
Second-generation drug-eluting stents (DES) are considered standard of care for revascularization of patients undergoing percutaneous coronary intervention. Besides the polymer and antiproliferative drug used, the metallic backbone of DES is an attractive target for further development. Ultrathin-strut DES (≤70 μm strut thickness) are more flexible, have an improved trackability and crossability compared to conventional second-generation DES. Importantly, ultrathin-strut DES reduce the risk of in-stent restenosis, thereby decreasing the risk of angiographic and clinical restenosis. In this narrative review, we will discuss the clinical outcomes of the commercially available ultrathin-strut DES.
摘要
第二代药物洗脱支架（DES）被认为是接受经皮冠状动脉介入治疗患者血运重建的标准治疗方法。除了所使用的聚合物和抗增殖药物外，DES的金属骨架也是进一步研发的一个有吸引力的目标。与传统的第二代DES相比，超薄支柱DES（支柱厚度≤70μm）更灵活，具有更好的跟踪性和通过性。重要的是，超薄支柱DES降低了支架内再狭窄的风险，从而降低了血管造影和临床再狭窄的风险。在这篇叙述性综述中，我们将讨论市售超薄支柱DES的临床结果。
相似文献
1
A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?
Heart Int. 2021 Dec 21;15(2):84-93. doi: 10.17925/HI.2021.15.2.84. eCollection 2021.
2
Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
J Pers Med. 2023 Apr 28;13(5):753. doi: 10.3390/jpm13050753.
3
Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease.
Circulation. 2018 Nov 13;138(20):2216-2226. doi: 10.1161/CIRCULATIONAHA.118.034456.
4
Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and Acute Coronary Syndromes.
JACC Cardiovasc Interv. 2021 Nov 22;14(22):2461-2473. doi: 10.1016/j.jcin.2021.09.028.
5
Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.
JAMA Cardiol. 2019 Jul 1;4(7):659-669. doi: 10.1001/jamacardio.2019.1776.
6
Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
Circ Cardiovasc Interv. 2019 Aug;12(8):e008024. doi: 10.1161/CIRCINTERVENTIONS.119.008024. Epub 2019 Aug 6.
7
Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
JACC Cardiovasc Interv. 2019 Sep 9;12(17):1650-1660. doi: 10.1016/j.jcin.2019.04.054. Epub 2019 Aug 14.
8
Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents.
Curr Opin Cardiol. 2020 Nov;35(6):705-711. doi: 10.1097/HCO.0000000000000786.
9
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
JACC Cardiovasc Interv. 2020 Jun 8;13(11):1343-1353. doi: 10.1016/j.jcin.2020.02.019.
10
Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review.
J Pers Med. 2022 Aug 25;12(9):1378. doi: 10.3390/jpm12091378.
引用本文的文献
1
Safety and efficacy of Evermine50 Everolimus-eluting coronary stent system in patients with native coronary artery lesions: Three-year outcomes from a single-center.
J Cardiovasc Thorac Res. 2025 Mar 18;17(1):58-65. doi: 10.34172/jcvtr.025.33123. eCollection 2025 Mar.
2
Advancements in Percutaneous Coronary Intervention Techniques: A Comprehensive Literature Review of Mixed Studies and Practice Guidelines.
Cureus. 2023 Jul 3;15(7):e41311. doi: 10.7759/cureus.41311. eCollection 2023 Jul.
3
Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents.
Indian Heart J. 2023 Jul-Aug;75(4):279-284. doi: 10.1016/j.ihj.2023.03.006. Epub 2023 Mar 25.
4
Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence.
J Clin Med. 2023 Feb 3;12(3):1238. doi: 10.3390/jcm12031238.
本文引用的文献
1
First Report of 3-Year Clinical Outcome After Treatment With Novel Resolute Onyx Stents in the Randomized BIONYX Trial.
Circ J. 2021 Oct 25;85(11):1983-1990. doi: 10.1253/circj.CJ-21-0292. Epub 2021 Jul 13.
2
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.
Eur Heart J. 2021 Jul 15;42(27):2643-2654. doi: 10.1093/eurheartj/ehab280.
3
Elastic stent recoil in coronary total occlusions: Comparison of durable-polymer zotarolimus eluting stent and ultrathin strut bioabsorbable-polymer sirolimus eluting stent.
Catheter Cardiovasc Interv. 2022 Jan 1;99(1):88-97. doi: 10.1002/ccd.29739. Epub 2021 May 7.
4
Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial.
Circulation. 2021 Jun;143(22):2155-2165. doi: 10.1161/CIRCULATIONAHA.120.052766. Epub 2021 Apr 7.
5
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
JACC Cardiovasc Interv. 2021 Mar 22;14(6):639-648. doi: 10.1016/j.jcin.2020.12.011.
6
Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex: Two-Year Outcomes of the TALENT Trial.
Circ Cardiovasc Interv. 2021 Mar;14(3):e010312. doi: 10.1161/CIRCINTERVENTIONS.120.010312. Epub 2021 Mar 9.
7
BioMatrix versus Orsiro biodegradable polymer stents in all-comer patients with coronary artery disease: the multicentre, randomised BIODEGRADE trial.
EuroIntervention. 2021 Apr 20;16(17):1404-1412. doi: 10.4244/EIJ-D-20-00185.
8
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
JACC Cardiovasc Interv. 2020 Jun 8;13(11):1343-1353. doi: 10.1016/j.jcin.2020.02.019.
9
Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
Circ Cardiovasc Interv. 2020 Jun;13(6):e008737. doi: 10.1161/CIRCINTERVENTIONS.119.008737. Epub 2020 May 29.
10
Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial.
Circulation. 2020 Jun 23;141(25):2052-2063. doi: 10.1161/CIRCULATIONAHA.119.040241. Epub 2020 May 21.
Zotero 插件